Key result
Edoxaban demonstrated similar or superior efficacy to warfarin for stroke prevention in nonvalvular atrial fibrillation, with a potentially lower risk of major bleeding.
Why the study?
Does edoxaban prevent thromboembolic events in patients with nonvalvular atrial fibrillation?
Does edoxaban prevent thromboembolic events in patients with nonvalvular atrial fibrillation?
Edoxaban is an effective and safe alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation, though head-to-head trials with other NOACs are lacking.
Answers are grounded in this paper and cite their sources.
Edoxaban lowers ischemic stroke and major bleeding versus warfarin; reinforces first-line NOAC use in NVAF.
INTRODUCTION: With the rising prevalence of nonvalvular atrial fibrillation (NVAF) in the general population, the development of new drugs for prevention of thromboembolic events is essential. Non-vitamin K antagonist oral anticoagulants (NOACs) have been shown to present a number of advantages over conventionally used agents, such as predictable pharmacokinetics and no requirement for continuous anticoagulant monitoring. The most recently approved NOAC for the NVAF indication is edoxaban. Several subgroup analyses from the edoxaban phase III ENGAGE AF-TIMI 48 trial have now been published, alongside meta-analysis data comparing the four currently approved NOACs. Consequently, an updated review of the literature is merited. Areas covered: A PubMed search using the terms 'edoxaban', 'non-vitamin K antagonist oral anticoagulant', 'ENGAGE AF-TIMI 48', and 'atrial fibrillation' was performed and results screened for the most relevant English language publications. The market position, pharmacological profile, clinical efficacy, safety and tolerability of edoxaban are presented and discussed. Expert commentary: Edoxaban has been shown to have an efficacy similar or superior to that of warfarin, with a potentially lower risk of major bleeding and predictable, dose-dependent pharmacology. In order to clarify its position within the NOAC market, head-to-head comparative studies are required.
No takes yet. Share an insight, caveat, or question.
Minguet et al. (2016) conducted a review in Nonvalvular atrial fibrillation (NVAF). Edoxaban vs. Warfarin was evaluated. Edoxaban demonstrated similar or superior efficacy to warfarin for stroke prevention in nonvalvular atrial fibrillation, with a potentially lower risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: